Mortality, predominantly due to cardiovascular events, is high in patients with chronic kidney disease (CKD) and left ventricular hypertrophy (LVH) is a strong risk factor. Vascular endothelial dysfunction (ED) is common in CKD, but its potential contribution to LVH in non-dialysis CKD is unknown. This study investigated the association of ED with LVH in non-dialysis CKD patients.
Introduction
Chronic kidney disease (CKD) is a major public health problem due to its high prevalence and associated increased mortality and morbidity. Cardiovascular disease is the single most common cause of heightened mortality and morbidity in patients with CKD; the mechanism remains poorly understood and hence, treatment is unsatisfactory. 1 The effect of renal impairment on coronary artery disease progression is seen across the whole spectrum of predialysis, dialysis, and post-renal transplantation patients. 2, 3 The cardiovascular complications in CKDs are associated with left ventricular hypertrophy (LVH), 4, 5 which is highly predictive of future cardiovascular morbidity and mortality. 6 Together with the traditional risk factors, it is hypothesized that non-traditional cardiac risk factors, i.e. anaemia, calcification, hyperhomocystinaemia, vitamin D deficiency, insulin resistance and oxidative stress, † This work was presented as an abstract at the American Society of Nephrology Kidney Week 2011. ‡ J.C.K. and D.B. are joint last authors.
play a role in the adverse cardiovascular outcome often seen in patients with CKD. 7 -9 Endothelial dysfunction (ED) is common in CKD manifesting as both albuminuria and a generalized impairment of relaxation in the systemic vascular tree. 10 ED is a risk factor for both the progression of CKD and for increased cardiovascular morbidity and mortality. 10 ED is linked with LV mass index (LVMI) in the general population independently of other CV risk factors, 11 and there is evidence that declining endothelial function may identify an adverse cardiac phenotype in healthy young adults. 12 Increased LVMI and eventually LVH is the hallmark of uraemic cardiomyopathy, the underlying substrate for fatal arrhythmias; the leading cause of death in advanced CKD. Inflammation, which is a potential mediator of ED, is present in patients with CKD 13 and has been shown to be associated with adverse cardiovascular outcomes in this patient population. 14 -16 An association between systemic inflammation and ED has also been shown in patients with pre-dialysis and post-transplant CKD. 8 However, the association between inflammation, ED, and cardiac hypertrophy has not been examined systematically in the non-dialysis CKD population.
The objective of this study was to investigate the relationship between inflammation, ED, and cardiac hypertrophy in pre-dialysis and post-transplant patients.
Methods

Patients
The study prospectively recruited 30 CKD patients, and 29 controls with normal renal function. Two cohorts constituted the CKD patient group: 17 pre-dialysis patients with Stages 3 -4 CKD, and 13 renal transplant patients. Estimated glomerular filtration rate (eGFR) was determined using the four-variable modification of diet in renal disease study equation. 17 Patients with Stages 3 -4 CKD had an eGFR between 60 and 15 mL/min/1.73 m 2 for at least 3 months. 18 Patients were excluded from the study if they had a prior diagnosis of heart failure, myocardial infarction, cancer, nephrotic-range proteinuria, bilateral arteriovenous fistulae, autoimmune disease, and/or active inflammatory processes with C-reactive protein (CRP) values .12 mg/L. Patients and controls underwent brachial artery flow-mediated dilatation (FMD) measurements, to assess ED. Two-dimensional echocardiography was used to estimate LV mass. A standardized questionnaire was used in every participant to obtain systematic information regarding conventional cardiovascular risk factors, including hyperlipidaemia, hypertension, diabetes, and a family history of CVD.
High-sensitivity C-reactive protein measurements
In patients and controls, venous blood was drawn from a large antecubital vein at study entry. The blood was centrifuged and serum aliquoted and stored at 2728C until analysis. CRP measurements were performed on the COBAS integra (Roche Diagnostic Ltd, Lewes, East Sussex, UK) using the CRP-latex assay in both the high-sensitivity application (analytical range 0.2 -12 mg/L) and the normal application (analytical range 2 -160 mg/L). Samples outside the analytical range of the high-sensitivity CRP-latex assay were analysed by the CRP-latex assay in the normal application.
Ultrasound imaging
In our vascular laboratory, all study subjects were assessed in a quiet purpose-built room maintained at constant temperature of 22 -248C; after 10 min of rest in the supine position; after 12 h overnight fasting. Patients and controls were asked not to take cardiac medications that could interfere with endothelial function 24 h prior to the study. Sublingual nitrate spray was, however, allowed at all times to relieve chest pain if required. None of the patients, however, required the use of sublingual nitrates ,12 h prior to testing. A standard high-definition imaging 3000 ultrasound system (ATL, Bothell, WA, USA) equipped with a 12 -5 MHz linear-array transducer was used for endothelial function measurements. The same trained physician who was blinded to the patient's clinical condition performed all scans. Repeating the ultrasound scans in 20 subjects, approximately 2 weeks apart, assessed intra-reader reproducibility for FMD. The observed within-subject variability of FMD measurements with our technique is 0.5 -1%.
Endothelial function and brachial artery flow-mediated dilatation
Ultrasound of the brachial artery is widely used to assess endothelial function. The right (or non-fistula arm) brachial artery was scanned in a longitudinal section 2 -10 cm above the elbow and its diameter measured continuously with on-line, wall-tracking software 19 for 1 min at baseline during 4.5 min of decreased blood flow (induced by inflation to 300 mmHg of a pneumatic cuff that was placed at a site distal to the segment of the artery being analysed), and for another 5 min during reactive hyperaemia after cuff release. After return to baseline, vessel diameter was again measured continuously for 1 and 5 min after administration of 50 mg of sublingual glyceryl trinitrate. FMD was defined as the maximum percentage increase in vessel diameter during reactive hyperaemia; endothelium-independent dilatation was defined as the maximum percentage increase in vessel diameter after sublingual glyceryl trinitrate, which is a direct nitric oxide donor.
Left ventricular hypertrophy and left ventricular mass index
All patients and control subjects in our study underwent two-dimensional echocardiogram to estimate the degree of LVH. Left parasternal long-axis view was used to estimate LV mass from linear measurements of the LV, interventricular wall thickness at base (IVSTD), LV maximum diameter (LVIDD), and posterior wall thickness (PWTD) in end diastole (in cm). LVMI was calculated using the Penn (geometric) LV mass formula, and indexed by height:
The relationship between height and LV mass is often non-linear and hence, we repeated the analyses with LVMI indexed for height 1.7 .
Statistical analysis
Results are presented as percentages for categorical data and analysed by the x 2 test as appropriate. Continuous normally distributed variables are expressed as means + 1 standard deviation (SD) and compared with Student's two-tailed unpaired t-test. Bivariate correlations between study variables were calculated by Pearson's correlation. All statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL, USA) version 17.0. A two-sided P-value of ,0.05 was considered to indicate statistical significance.
Results
The patients and controls were age-and gender-matched (58% females and 33% males). Body mass index (BMI) was not different between the two groups ( Table 1) . The two CKD patient cohorts had comparable baseline clinical characteristics at study entry with respect to age, blood pressure, and cholesterol ( Table 2 ). The only significant difference observed was that the post-renal transplantation patients had a higher eGFR and a lower BMI than the pre-dialysis group. For the kidney transplant patients, the duration posttransplantation at the study was 56 + 58 months. In the CKD and kidney transplantation population, 14 of 30 (46%) were treated with aspirin or clopidogrel, 19 (63%) were on ace inhibitors or angiotensin receptor blockers, 7 (23%) were on beta blockers, 10 (33%) were on diuretics, 15 (50%) were on calcium channel blockers, 16 (53%) were on statins, and 3 (10%) were receiving erythropoietin. Both cohorts of CKD patients, when compared with controls, had higher CRP levels (3.9 + 2.8 vs. 1.0 + 0.7 mg/L; P , 0.001), poorer endothelial function i.e. lower FMD (3.2 + 2.1 vs. 6.1 + 1.9%; P , 0.001), and an increased LVMI (146.1 + 40.2 vs. 105.3 + 26.2 g/m; P , 0.001; Table 1 ). There was no significant difference in these variables between pre-dialysis and post-transplantation patients ( Table 2) .
LVMI had a significant negative correlation with FMD (Pearson's r ¼ 20.371, P ¼ 0.043) in both cohorts of CKD patients ( Figure 1) . CRP levels showed a significant negative correlation with FMD (Pearson's r ¼ 20.741, P , 0.001) in CKD patients ( Figure 2) .
To analyse the relationship between FMD and LVMI further, we divided the CKD patients into two categories based on FMD (Table 3) . We took the mean FMD of the control group minus 2 SD to provide a cut off FMD of 2.3%. LVMI was significantly higher in patients with a higher degree of ED, represented by FMD ,2.3% (161.9 + 48.9 vs. 130.4 + 20.7 g/m; P ¼ 0.033). Poorer endothelial function (FMD ,2.3%) was also significantly associated with a higher CRP (5.6 + 2.4 vs. 2.1 + 2.0 mg/L; P , 0.001).
We examined the relationships with LVM indexed for height 1.7 , as it is suggested to be a better predictor of adverse outcomes. LVM indexed for height 1.7 Table 4 ). However, when the correlation was adjusted for hypertension, the significance was eliminated (adjusted beta ¼ 20.191; P ¼ 0.174; Table 5 ).
We performed multivariate analysis with separate models using systolic, diastolic, and mean blood pressures. In a model adjusted for age, diabetes, smoking and systolic blood pressure (BP), decreasing FMD was independently associated with increasing LVMI (adjusted beta ¼ 20.341; P ¼ 0. 
Discussion
This pilot study demonstrated, for the first time an association between ED as measured by FMD and LVH in pre-dialysis and posttransplant CKD patients. The patients with impaired endothelial function (FMD ,2.3%; 2 SD below the mean for controls) had similar age, blood pressure, haemoglobin, and kidney function, but higher CRP and LV mass compared with those with FMD ≥2.3%. In the present study, CKD patients had increased systemic inflammation, ED and LVH in comparison to healthy volunteers, in line with findings in previous reports. 8, 20 Within the CKD patients, a significant relationship between inflammation and ED was observed in agreement with previous studies. 8, 20, 21 Traditional CV risk factors, such as hypertension, hyperlipidaemia, smoking, and diabetes, contribute to the high CV morbidity and mortality rates seen in CKD patients, but do not explain the entire risk. 7 The significantly increased prevalence of CV disease in CKD patients compared with the general population needs to be explained by other non-traditional factors, and this study attempts to address this issue. Inflammation causes ED and hence may be a common mediator for endothelial injury related to all non-traditional risk factors. As atherosclerosis is recognized as an inflammatory disease, inflammation may also be the common mediator for all traditional risk factors causing ED. 7, 22 In support of this argument, our findings demonstrate a linear relationship between inflammation and ED. However, more evidence is necessary to prove a cause-effect relationship.
In the general population, endothelial function worsens in the presence of traditional risk factors. There is also evidence of an additive effect on the worsening of endothelial function with the presence of more than one of the traditional risk factors. 23 Moreover, in the general population, ED has been shown to be an independent predictor of adverse outcomes. 24 Endothelial function is highly abnormal in patients with CKD and worsens with decreasing kidney function. Hence, it may be a good marker and potentially a surrogate for subsequent CV events. 8 The present study investigated non-dialysis CKD and kidney transplant patients and demonstrated a relationship of worsening endothelial function with increasing LVH, which predicts further adverse events. LVH is highly predictive of future CV morbidity and mortality. 6 LVH is common in patients with CKD and ESRD. 25 -27 In CKD and ESRD patients, LVH progresses with hypertension and anaemia. 25, 28, 29 The anaemia-related LVH is proposed to be related to inflammation and oxidative stress. 30 However, the precise mechanisms underlying the development of LVH in CKD patients are still not clearly defined. In hypertension, ED is proposed to have a key role in the development of LV remodelling. Nitric oxide released from healthy endothelium prevents cardiac hypertrophy, 31 whereas endothelin, a powerful microvascular constrictor and pro-inflammatory substance also released from a dysfunctional endothelium, promotes cardiac hypertrophy. 32 In addition, traditional risk factors that are associated with worsening endothelial function have also been linked to increased large artery stiffness, 33, 34 which itself is an important predictor of outcome in patients with CKD. 35 In healthy individuals, a decline in global endothelial function is associated with increased aortic stiffness and augmentation index. 36 In CKD patients, there is remodelling of the arterial system that results in arterial stiffening. 37 -39 Enhanced wave reflections as a result of this arterial stiffening provide a potential underlying mechanism linking ED with LV hypertrophy in CKD patients. This is supported by evidence from animal models where increased arterial wave reflections were accompanied by concentric hypertrophy and from hypertensive patients where decreased wave reflection magnitude contributed to LV mass regression. 40, 41 This is particularly important clinically as it has been demonstrated that arterial wave reflections represent a strong risk factor for the development of congestive heart failure in the general population. 42 This study demonstrated an association of ED with LVH suggesting a cause -effect relationship. However, we have not carried out experiments to directly investigate causality. Patients on dialysis exhibit severely abnormal endothelial function and a high prevalence of LVH. 8, 25, 26 The relationship between ED and LVH has been demonstrated in a study with 104 patients on maintenance haemodialysis. 43 LVH was present in 69%; and those with LVH had higher rates of hypertension and anaemia. Our study is the first study to demonstrate a relationship between ED with LVH in non-dialysis CKD patients.
In the general population, associations have been made between ED and systemic inflammation. 22 Recent evidence implies that inflammation, oxidative stress, and ED in CKD are embraced in a mutual amplifying loop. Inflammation from any cause induces the activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase that leads to reactive oxygen species (ROS) generation, which, in turn, leads to ED. Moreover, increased asymmetric dimethyl arginine levels, largely implicated in the pathogenesis of ED in CKD, can trigger inflammation by activating NADPH and generating ROS. 44 Even though the precise mechanisms underlying the development of ED and LVH in CKD patients are not well understood, associations have been identified between ED and systemic inflammation. 22 Establishing how exactly these factors influence each other and contribute to the pathogenesis of CV disease in CKD is not only clinically and prognostically important, but will also lead to a better understanding of the disease process and the development of preventative therapies in the future. LVH is associated independently with chronic lowgrade systemic inflammation. 45 Low-grade inflammation and ED are almost inseparable in the non-CKD population meaning any relationship with arterial stiffening and increased cardiac afterload may be interdependent. 46 We are still in the initial stages of understanding what drives the ED, inflammation, and cardiomyopathy in CKD. Once these mechanisms are understood, new therapies can be developed to modulate the CV risk in the CKD patient population.
Interestingly, in our study, poorer endothelial function was significantly associated with higher LV mass when adjusted for SBP, DBP, and mean arterial BP with other CV risk factors; suggesting that the effect of ED may be independent of concomitant BP, but not the effect of pre-existing hypertension and its treatment.
Limitations of the study
The study proposes a relationship of inflammation with ED and LVMI but without longitudinal data. The sample size is small and as a result it was not possible to match pre-dialysis and post-kidney transplantation patients by eGFR to compare high-sensitivity CRP (hsCRP) levels and LVMI. The study demonstrates an association but not a cause -effect relationship.
Conclusion
The present pilot study demonstrated an important relationship between LVH, a predictor of CV events and ED in pre-dialysis, and post-kidney transplantation patients. The ED, in turn, was related to low-grade systemic inflammation, possibly mediated by traditional and non-traditional risk factors. This study proposes that inflammation may have an important role in the development of LV hypertrophy through ED. We propose that further studies need to be done to investigate the mechanisms of non-traditional and traditional cardiovascular risk factor-mediated ED and LVH in order to find new therapies to reduce cardiovascular morbidity and mortality in this expanding patient group.
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